Abstract
755P Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have